Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 2019Website:
http://www.inmunebio.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
INMB Latest News
INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy. XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study. Financially, INMB faces cash challenges but continues to make progress with a potential transformative data readout by spring 2024.
INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Joel Beatty - Baird Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Analysts at Baird initiated coverage of the immunology company INmune Bio with a price target more than double its current share price. The firm issued an Outperform rating and target price of $16.
INmune Bio: Alzheimer's Disease Treatment Lottery Ticket.
What type of business is INmune Bio?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
What sector is INmune Bio in?
INmune Bio is in the Healthcare sector
What industry is INmune Bio in?
INmune Bio is in the Biotechnology industry
What country is INmune Bio from?
INmune Bio is headquartered in United States
When did INmune Bio go public?
INmune Bio initial public offering (IPO) was on 04 February 2019
What is INmune Bio website?
https://www.inmunebio.com
Is INmune Bio in the S&P 500?
No, INmune Bio is not included in the S&P 500 index
Is INmune Bio in the NASDAQ 100?
No, INmune Bio is not included in the NASDAQ 100 index
Is INmune Bio in the Dow Jones?
No, INmune Bio is not included in the Dow Jones index
When does INmune Bio report earnings?
The next expected earnings date for INmune Bio is 07 August 2024